Ventilator-associated pneumonia de-escalation — FFICM MCQ

Correct answer: C — De-escalate to a narrower agent guided by sensitivities

The correct answer is C, de-escalate to a narrower agent guided by sensitivities. Once culture results identify a fully sensitive organism and the patient is clinically improving off vasopressors, continued broad-spectrum cover with meropenem and vancomycin is no longer justified; both empirical MRSA cover (vancomycin) and carbapenem-level Gram-negative cover become unnecessary once Haemophilus influenzae, fully sensitive, is confirmed with negative blood cultures and a negative MRSA screen. UK stewardship policy under Start Smart Then Focus mandates a formal antimicrobial review at 48 to 72 hours specifically to de-escalate broad-spectrum agents to pathogen-directed narrow-spectrum treatment once microbiology is available. This is doubly important here because worsening renal function increases the risk of vancomycin- and meropenem-related nephrotoxicity and accumulation, so narrowing therapy (for example to amoxicillin or co-amoxiclav depending on beta-lactamase status) both treats the confirmed pathogen and reduces harm. Why the other options are wrong: A. Continue meropenem and vancomycin for 14 days: this perpetuates unnecessary broad-spectrum and glycopeptide exposure against an organism proven sensitive to narrower agents, increasing resistance selection pressure and nephrotoxic risk in a patient with deteriorating renal function. E. Stop antibiotics immediately: there is a confirmed causative organism from BAL requiring a completed treatment course; stopping entirely would leave the pneumonia undertreated. D. Add an aminoglycoside for synergy: synergy dosing is reserved for specific indications such as enterococcal endocarditis, not sensitive H. influenzae pneumonia, and would add further nephrotoxic burden. B. Change to antifungal therapy: there is no fungal isolate or clinical indication; the BAL grew a bacterial pathogen fully sensitive to standard antibiotics. Key point: once a fully sensitive pathogen is identified and the patient is improving, active de-escalation to the narrowest effective agent is a stewardship duty, particularly when ongoing renal impairment raises the toxicity cost of unnecessary broad-spectrum therapy.

Reference: UK Health Security Agency / Department of Health, Start Smart Then Focus: Antimicrobial Stewardship Toolkit for Inpatient Care Settings, 2023 update, gov.uk